Before the COVID-19 pandemic, the vast majority of Americans – regardless of their ideological leanings – simply trusted the medical establishment. That trust was devastated by the experience of the pandemic. According to polling, in April 2020 – at the outbreak of the pandemic – 71.5 percent of respondents reported having “a lot of trust” in physicians and hospitals. By January 2024, that number had plummeted to 40.1 percent.

This loss of faith, while certainly understandable, is untenable. Trust is at the core of the doctor-patient relationship. Patients must be able to rely on the medical advice that they are given by doctors and medical professionals. 

Unfortunately, trust in our healthcare system and its institutions has been undermined by a belief that decisions are being made – not based on what is in the best interest of Americans' healthcare – but what is in the best interest of corporate bottom lines.

To restore faith in our system, we need research and treatment that is focused on the patient’s health – not just profit.

That is exactly why I co-authored a recent study, along with a number of my colleagues – a first-of-its-kind human observational study of the application of ivermectin mebendazole in the treatment of cancer.

In addition to myself, the manuscript was authored by........

© Townhall